Cognito Therapeutics Presents New Data on Spectris in Alzheimer's Disease at AD/PD 2026
Summary
Cognito Therapeutics presented new research from its investigational Spectris therapy at the AD/PD 2026 International Conference in Copenhagen. The presentations explored how gamma sensory stimulation may influence brain network activity and EEG biomarkers in Alzheimer's disease. Analysis of the OVERTURE feasibility study showed that Spectris-treated patients demonstrated attenuation of EEG slowing compared with sham, and reductions in EEG slowing correlated with reduced functional decline and less brain volume loss.
Why it matters
These findings strengthen the scientific foundation for gamma sensory stimulation as a potentially disease-modifying therapy for Alzheimer's disease. By linking neurophysiological changes measured by EEG to functional and structural clinical outcomes, Cognito is building a compelling biomarker-guided development program that could accelerate regulatory pathways and provide a non-invasive treatment option for the more than 55 million people worldwide affected by Alzheimer's.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial